Hedwig Sutterlüty

6PUBLICATIONS
1CO-AUTHORS
Proteins and peptidesSignal transductionCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 14, 2025
The Lysine at Position 177 Is Essential to Limit the Inhibitory Capacities of Sprouty4 Protein in Normal and Cancer-Derived Cells.

Maximilian Schiwek, Kathrin Ruhdorfer, Christoph Pfurner

|Jun 28, 2023
Signal Transduction as an Assimilation of Signals with Different Origins and Different Intracellular States.

Klaus Holzmann, Hedwig Sutterlüty

|Oct 14, 2022
Emerging Roles of Exosomes in Cancer for Possible Clinical Use.

Hedwig Sutterlüty, Klaus Holzmann

|Nov 13, 2021
Sprouty3, but Not Sprouty1, Expression Is Beneficial for the Malignant Potential of Osteosarcoma Cells.

Anna Zita Mehira Kamptner, Christoph-Erik Mayer, Hedwig Sutterlüty

|Mar 06, 2021
A Sprouty4 Mutation Identified in Kallmann Syndrome Increases the Inhibitory Potency of the Protein towards FGF and Connected Processes.

Astrid Stütz, Anna Z M Kamptner, Hedwig Sutterlüty

|Aug 04, 2019
Sprouty3 and Sprouty4, Two Members of a Family Known to Inhibit FGF-Mediated Signaling, Exert Opposing Roles on Proliferation and Migration of Glioblastoma-Derived Cells.

Burcu Emine Celik-Selvi, Astrid Stütz, Christoph-Erik Mayer

Pageof 1

Frequent Collaborators

2 joint publications

Klaus Holzmann